SEC Form 4 · accession 0001209191-17-060104
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Foley
Director
Period of report
Nov 7, 2017
Accepted (ET)
Nov 9, 2017 · 7:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 7, 2017 | P | 19,500 | $26.9458 | A | 19,500 | I | See footnote |
| Common StockF2 | Nov 7, 2017 | P | 500 | $27.45 | A | 20,000 | I | See footnote |
| Common Stock | holding | — | — | — | 6,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Table I, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.425 to $27.425. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.